How to manage your dog's shedding this summer

Every morning, I wake to a fresh layer of golden fuzz covering the floor. Musafir, our golden retriever, is shedding with great enthusiasm. If you're a pet parent in India right now, chances are your home looks similar and you're wondering how to manage the shedding.
Summer shedding is natural. Most dogs shed to some degree year-round, but you'll notice a marked increase when the weather changes. As temperatures rise, dogs lose their winter coats. This seasonal shedding helps them adapt to warmer weather. While we can't stop the shedding, we can manage it.
Also read: How to safely enjoy your pet's day at the beach
One of the simplest, most effective ways to deal with shedding is brushing. Regular brushing removes loose fur, reduces tangles, and helps distribute natural oils across your pet's coat. The type of brush and frequency will vary depending on your dog's breed and coat type.
For double-coated breeds like golden retrievers, huskies and German shepherds, a slicker brush or an undercoat rake used daily or every other day during the shedding season works wonders. These breeds have a dense undercoat that sheds in clumps, and tools designed specifically to reach that layer make a huge difference. Short-haired breeds such as beagles or dachshunds benefit from a rubber curry brush or a grooming glove. Poodles and other curly coated dogs don't shed much but still require grooming to prevent matting—use a pin brush or a comb a few times a week.
Vacuuming is another way of dealing with the fur. Invest in a vacuum cleaner with a good pet hair attachment and use it frequently. Wash cushion covers, throws and rugs often.
You might also consider adding omega oil supplements to your pet's diet, after consulting your vet. Omega-3 and omega-6 fatty acids help support skin health and coat condition, reducing dryness and dandruff, both of which can exacerbate shedding. Of course, results aren't immediate; it takes a few weeks of regular use for the effects to show.
The summer shedding phase can last from a few weeks to a couple of months, depending on your dog's breed, age, and health. Dogs that spend a lot of time outdoors are influenced by seasonal changes and natural light, while those kept primarily indoors in air-conditioned environments may shed more year-round. If your pet's shedding seems excessive, or if it's accompanied by bald spots, itching, redness or any signs of discomfort, it's important to dig deeper.
Skin infections, allergies, hormonal imbalances or parasitic infestations can all cause abnormal shedding or poor coat quality. In India, tick-borne illnesses such as ehrlichiosis or babesiosis can also affect skin and coat health. If in doubt, visit your vet for a thorough checkup.
This brings me to Ella, a golden retriever I recently met. Her parent, frustrated with her summer shedding, had shaved her coat down to the skin. It's a common enough reaction, driven by the belief that removing fur will help dogs feel cooler and reduce shedding. Unfortunately, it does neither.
Shaving a double-coated dog can cause more harm than good. Their coat is designed to provide insulation—it keeps them warm in winter and cool in summer by regulating body temperature and protecting the skin from the sun. When you shave it, you disrupt this natural process. What's more, the undercoat often grows back faster and denser than the topcoat, leading to permanent damage to coat texture. It also increases the risk of sunburn and skin irritation.
Instead of shaving, focus on helping your dog stay cool in other ways. Provide plenty of fresh water, ensure there are shaded spots or cool indoor areas for them to rest and avoid walks during the hottest parts of the day.
Fur on the sofa, on your clothes or in your morning tea can be frustrating, but is part of the package when you have a pet, and can be managed easily.
Nameeta Nadkarni is a veterinary soft tissue surgeon and pet blogger from Mumbai.
Also read: Monsoon pet travel guide: hikes, tips and essentials

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hindustan Times

14-06-2025

• Hindustan Times

Health Talk: Bharat Biotech-GSK's Shigella vaccine candidate holds promise

Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3, the companies announced in a joint statement on Thursday. The partnership will mark a critical step in the advancement of this promising vaccine, targeting Shigellosis—a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries. India is also impacted. A 2021 study published in the Indian Journal of Medical Biology— Antimicrobial Resistant Shigella in North India Since the Turn of the 21st Century — talks about how the ubiquitous presence and rampant spread of Shigellosis in Asian and African countries, along with the emergence of antibiotic-resistant strains, is particularly concerning. 'The scientific community must focus efforts to identify the drugs most suitable for empirical therapy according to these antibiograms. To decrease the morbidity and mortality associated with diarrhea in our country, we not only need newer antimicrobials, cost-effective vaccines but also public health measures such as safe drinking water and sanitation…,' concluded researchers in the paper. Talking about the partnership, Bharat Biotech executive chairman Krishna Ella said, 'As the market leader in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi, Bharat Biotech is proud to partner with GSK to develop a next-generation Shigella vaccine candidate, for a severe form of bacterial diarrhoea affecting millions of children under five.' 'With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low- and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment. The use of Generalised Modules for Membrane Antigens (GMMA) technology reflects our mission to deliver accessible vaccines that protect and improve lives worldwide,' Ella added. According to the statement issued, altSonflex1-2-3 has already shown encouraging results in early-stage clinical trials. 'A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it read. The vaccine candidate represents one of the most advanced Shigella vaccine candidates globally. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative GMMA-based platform, and robust early clinical results. GMMA technology is an innovative platform that uses bacterial outer membranes to deliver the O Antigen to the immune system. This approach allows for high-yield production with a simple and cost-effective manufacturing process, offering a pathway to create affordable vaccines for underserved populations. As part of this agreement, Bharat Biotech will lead the further development of the vaccine candidate, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing. GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. 'With young children in lower-income countries disproportionately impacted by Shigella, the development of a low-cost vaccine is an important goal for global public health. With no licensed vaccines widely available, the development of our Shigella vaccine candidate, which has demonstrated promising clinical trial results, fills us with immense pride,' GSK chief global health officer Thomas Breuer said. Having effective vaccines, which are also cost-effective, can reduce the overall disease burden significantly.

News18

11-06-2025

• News18

Bharat Biotech's Nasal Vaccine 'Can Adapt' To New COVID Strains, Regulatory Nod Awaited

Last Updated: Bharat Biotech told News18 that the company's COVID-19 vaccine platforms are enabled for 'adaptation'. However, restarting production needs regulatory agency approvals. Amid rising concerns over the JN.1 COVID-19 variant, Indian vaccine maker Bharat Biotech has stated its preparedness to address the emerging variant with its 'adaptable" vaccine platforms. However, production will only restart with regulatory approval. Suchitra Ella, Managing Director of Bharat Biotech, told News18 that the company is 'actively monitoring the ongoing situation" and remains prepared to respond, emphasising the adaptability of its vaccine platforms to evolving strains. 'We remain committed to ensuring that our vaccine platforms are adaptable and ready to respond to evolving strains," she said. As of 11 June, India has recorded 7,121 active COVID-19 cases, according to the Union Health Ministry's official COVID-19 dashboard. Delhi, Gujarat, Kerala, Maharashtra, and West Bengal report the majority of these cases. Highlighting the benefits of its nasal vaccine, iNCOVACC, Ella told News18 that its intranasal COVID-19 vaccine offers targeted upper respiratory tract protection, ease of administration without needles, and adaptability to circulating strains. The company affirms its proactive monitoring and preparedness: 'actively monitoring the situation and well-positioned to respond effectively if the need arises." iNCOVACC, India's first intranasal COVID-19 vaccine, is available as a booster dose for adults. Its needle-free design, with drops instilled into each nostril, eliminates the need for trained healthcare professionals for administration. Ella confirmed the adaptability of both the injectable and intranasal COVID-19 vaccine platforms. 'However, any decision to restart production is contingent upon regulatory agency approvals. We continue to work in close coordination with regulatory bodies to ensure preparedness always aligns with evolving scientific and safety standards," she explained in an emailed interview with News18. While several countries recommend booster doses for high-risk and vulnerable groups, experts in India have not yet issued such a recommendation. 'Booster doses have been recommended in several countries for high-risk and vulnerable populations. Booster doses in our country are subject to approval from national regulatory agencies." Ella clarified that COVID-19 vaccine production would only recommence if directed by the national regulatory body. She also revealed the extent of vaccine wastage due to declining demand: 'As of early 2022, production of COVAXIN was paused in response to reduced demand and the cancellation of issued purchase orders. Subsequently, we proceeded with the destruction of around 20 crore doses of bulk and almost 5 crore doses of vaccines in vials." A senior health ministry source informed News18 that the recent rise in COVID-19 cases is no cause for panic, likening the current trend to seasonal influenza. While no immediate vaccination is necessary, basic precautions are advised, especially for those exhibiting symptoms. 'Wear a mask if you have a cough or cold, and request those around you to do the same, and people with co-morbidities like diabetes or kidney disease should remain particularly cautious during this period." Although booster shots may not be currently necessary in India, given the mild, influenza-like illness caused by current variants, the preparedness of Indian vaccine companies and their adaptable platforms demonstrate the nation's capacity for rapid response should more severe COVID-19 variants or other pathogens emerge.

Mint

08-06-2025

• Mint

Covaxin maker Bharat Biotech's nasal vaccine ready to take on new covid strains

New Delhi: Bharat Biotech International Ltd, which developed the covaxin vaccine to protect against earlier variants of covid-19, says its intranasal and injectable vaccine platforms are ready to be adapted for new strains of the disease. India has recorded 5,755 active covid cases, according to the Union health ministry's data issued on Sunday. The nation also reported four new fatalities in the last 24 hours, taking the total covid death toll since 1 January to 59. Health officials have identified two new JN.1 covid variants as the cause of the fresh wave of the infectious disease. Suchrita Ella, managing director of Bharat Biotech, said the company's nasal vaccine iNCOVACC is 'specifically designed for flexibility to adapt to circulating strains, protection in upper respiratory tract, and easy administration without injections". 'Bharat Biotech's covid-19 vaccine platforms, both the injectable and intranasal versions, are enabled for adaptation. However, any decision to restart production is contingent upon regulatory agency approvals," she said in an email interview. 'We continue to work in close coordination with regulatory bodies to ensure preparedness always aligns with evolving scientific and safety standards," Ella said, adding that the company is monitoring the situation and is "well positioned to respond effectively". Also read | Covid cases are rising again. Should we be worried? Bharat Biotech and Serum Institute of India manufactured billions of doses of vaccines for Indians and for supplying to more than 100 countries during the first few waves of the covid pandemic. The last covid vaccine batches were manufactured a year ago, with no visibility on new stocks. Dr. Soumya Swaminathan, a former chief scientist at the World Health Organization (WHO), recently emphasized the need for vaccine manufacturers to update their formulas based on new variants, warning that vaccines developed for the original covid strain would offer little protection now. Bharat Biotech halted production of covaxin due to a decline in demand in early 2022 and destroyed significant quantities of its vaccine stock. 'Subsequently, we proceeded with the destruction of about 200 million doses of bulk and about 50 million doses of vaccines in vials," Ella said. Asked if booster doses should be given to high-risk populations, Ella said that remained subject to national regulatory approval. Also read | India steps up surveillance as covid-19 cases surge in Hong Kong and Singapore India's covid preparedness The Union health ministry, while stating that most current covid cases are mild, has directed states and union territories to increase testing and ensure medical preparedness across health facilities, reviewing the availability of oxygen, isolation beds, ventilators, and essential medicines. A nationwide mock drill was conducted last week to assess the functionality of oxygen supply systems in hospitals. The Union government has also advised the public to practise covid-appropriate behaviour, especially avoiding crowded places when unwell and seeking medical intervention. State and district surveillance units are also closely monitoring cases of influenza-like illness (ILL) and severe acute respiratory illness (SARI). As per government guidelines, all admitted SARI patients and 5% of ILI cases are to be tested for covid. Scientists at the Indian Council of Medical Research (ICMR) are conducting genome sequencing of positive samples to track the variants. The latest covid wave is attributed to two new coronavirus variants—NB.1.8.1 and LF.7, which are mutations of the Omicron offspring JN.1 variant. Kerala has reported the maximum number of covid cases this year, at 1,373, followed by Maharashtra (510), Delhi (457), Gujarat (461), and West Bengal (431). According to the Union health ministry, 760 people have recovered from covid in the last 24 hours, bringing the total number of recoveries this year to 5,484. Also read | The official 'data fog' on India's covid toll has finally cleared up. Here's what we know now.